USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$123.64M
Market Cap
-
P/E Ratio
-1.08
EPS
$2.25
52 Week High
$0.08
52 Week Low
HEALTHCARE
Sector
| Field | Value (None) |
|---|---|
| Gross Profit | $86K |
| Total Revenue | $86K |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$24M |
| Selling General And Administrative | $13M |
| Research And Development | $11M |
| Operating Expenses | $24M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | $303K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $246K |
| Income Before Tax | -$47M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$48M |
| Ebitda | -$48M |
| Net Income | -$47M |
| Field | Value (None) |
|---|---|
| Total Assets | $20M |
| Total Current Assets | $20M |
| Cash And Cash Equivalents At Carrying Value | $15M |
| Cash And Short Term Investments | $15M |
| Inventory | - |
| Current Net Receivables | $4.6M |
| Total Non Current Assets | $485K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $297K |
| Other Non Current Assets | - |
| Total Liabilities | $7.1M |
| Total Current Liabilities | $7M |
| Current Accounts Payable | $6.1M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $184K |
| Total Non Current Liabilities | $74K |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $258K |
| Other Current Liabilities | $726K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $13M |
| Treasury Stock | - |
| Retained Earnings | -$158M |
| Common Stock | $20K |
| Common Stock Shares Outstanding | $34M |
| Field | Value (None) |
|---|---|
| Operating Cashflow | -$13M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $246K |
| Capital Expenditures | $8K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$8K |
| Cashflow From Financing | $21M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$47M |
| Field | Value (None) |
|---|---|
| Gross Profit | $86K |
| Total Revenue | $86K |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$24M |
| Selling General And Administrative | $13M |
| Research And Development | $11M |
| Operating Expenses | $24M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | $303K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $246K |
| Income Before Tax | -$47M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$48M |
| Ebitda | -$48M |
| Net Income | -$47M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Incannex Healthcare Ltd ADR is a leading innovator in the burgeoning medicinal cannabinoid market, headquartered in Sydney, Australia. The company specializes in the research, development, and commercialization of cutting-edge cannabinoid therapies aimed at improving patient outcomes and addressing significant unmet medical needs. With a strong pipeline of clinical programs and a commitment to regulatory compliance, Incannex is well-positioned to capitalize on the growing demand for scientifically validated therapeutic products, establishing itself as a key player in the healthcare sector.